Tumor treating induced fields: a new treatment option for patients with glioblastoma

被引:0
|
作者
Cai, Zehao [1 ]
Yang, Zukai [2 ]
Wang, Ying [2 ]
Li, Ye [3 ]
Zhao, Hong [3 ]
Zhao, Hanwen [4 ]
Yang, Xue [1 ]
Wang, Can [1 ]
Meng, Tengteng [3 ]
Tong, Xiao [2 ]
Zheng, Hao [2 ]
He, Zhaoyong [2 ]
Niu, Chunli [3 ]
Yang, Junzhi [3 ]
Chen, Feng [1 ]
Yang, Zhi [5 ]
Zou, Zhige [4 ]
Li, Wenbin [1 ]
机构
[1] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurooncol, Canc Ctr, Beijing, Peoples R China
[2] Capital Med Univ, Sch Basic Med Sci, Beijing, Peoples R China
[3] Kunlun Tripot Beijing Med Technol Co Ltd, Beijing, Peoples R China
[4] Huazhong Univ Sci & Technol, Sch Integrated Circuits, Wuhan, Hubei, Peoples R China
[5] Capital Med Univ, Sch Biomed Engn, Beijing, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2024年 / 15卷
关键词
electromagnetic therapy; glioblastoma; central nervous system; electromagnetic induction; transformer; NEWLY-DIAGNOSED GLIOBLASTOMA; ELECTROMAGNETIC-FIELDS; CELL-PROLIFERATION; 100; HZ; CANCER; TRIAL; CHEMOTHERAPY; TEMOZOLOMIDE; METASTASES; CARCINOMA;
D O I
10.3389/fneur.2024.1413236
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Currently, a range of electromagnetic therapies, including magnetic field therapy, micro-currents therapy, and tumor treating fields, are under investigation for their potential in central nervous system tumor research. Each of these electromagnetic therapies possesses distinct effects and limitations. Our focus is on overcoming these limitations by developing a novel electric field generator. This generator operates by producing alternating induced currents within the tumor area through electromagnetic induction.Methods Finite element analysis was employed to calculate the distribution of electric fields. Cell viability was assessed using the CCK-8 assay. Tumor volumes and weights served as indicators to evaluate the effectiveness of TTIF. The in-vivo imaging system was utilized to confirm tumor growth in the brains of mice.Results TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo.Conclusion TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic GBM.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Delayed Pseudoprogression in Glioblastoma Patients Treated With Tumor-Treating Fields
    Saito, Norihiko
    Hirai, Nozomi
    Sato, Sho
    Hayashi, Morito
    Iwabuchi, Satoshi
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [22] Quality of Life in Patients With Glioblastoma Treated With Tumor-Treating Fields
    Kwan, Kevin
    Schneider, Julia R.
    Boockvar, John A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2018, 319 (17): : 1822 - 1823
  • [23] INSTITUTIONAL COMPLIANCE WITH TUMOR TREATING FIELDS FOR GLIOBLASTOMA
    Bonomi, Robin
    Burmeister, Jay
    Dominello, Michael
    NEURO-ONCOLOGY, 2018, 20 : 121 - 121
  • [24] Current usage of tumor treating fields for glioblastoma
    Lassman, Andrew B.
    Joanta-Gomez, Adela E.
    Pan, Peter C.
    Wick, Wolfgang
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [25] REAL-WORLD SURVEILLANCE DATA FOR TUMOR TREATING FIELDS AFFIRM THE TOLERABILITY OF TUMOR TREATING FIELDS FOR THE TREATMENT OF GLIOBLASTOMA IN THE UNITED STATES
    Tran, David
    NEURO-ONCOLOGY, 2018, 20 : 198 - 198
  • [26] TUMOR TREATING FIELDS TREATMENT FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA: A COST-EFFECTIVENESS ANALYSIS FOR SWEDEN
    Guzauskas, G. F.
    Wang, B. C. M.
    Kinzel, A.
    Proescholdt, C.
    NEURO-ONCOLOGY, 2018, 20 : 256 - 256
  • [27] The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV
    Krigers, Aleksandrs
    Pinggera, Daniel
    Demetz, Matthias
    Kornberger, Lisa-Marie
    Kerschbaumer, Johannes
    Thome, Claudius
    Freyschlag, Christian F.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [28] Eighteen years' experience with tumor treating fields in the treatment of newly diagnosed glioblastoma
    Vymazal, Josef
    Kazda, Tomas
    Novak, Tomas
    Slanina, Petr
    Sroubek, Jan
    Klener, Jan
    Hrbac, Tomas
    Syrucek, Martin
    Rulseh, Aaron M. M.
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [29] Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
    Fabian, Denise
    Eibl, Maria del Pilar Guillermo Prieto
    Alnahhas, Iyad
    Sebastian, Nikhil
    Giglio, Pierre
    Puduvalli, Vinay
    Gonzalez, Javier
    Palmer, Joshua D.
    CANCERS, 2019, 11 (02):
  • [30] Aurora kinase inhibition to enhance Tumor Treating Fields efficacy in glioblastoma treatment
    Bartmann, Paula
    Roosz, Silvia
    Temme, Achim
    Giladi, Moshe
    Kirson, Eilon D.
    Plati, Yoram
    Weinberg, Uri
    Kinzel, Adrian
    Leidgens, Verena
    Krex, Dietmar
    CANCER RESEARCH, 2019, 79 (13)